Affimed Completes TandAb Development Candidate Activities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Affimed Completes TandAb Development Candidate Activities Meeting Amphivena's and Janssen's Criteria and Achieves Milestone Ahead of Schedule

HEIDELBERG, Germany, March 24, 2015 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD ), a clinical-stage biopharmaceutical company developing targeted cancer immunotherapies today announced the achievement of the second milestone in its development partnership with Amphivena Therapeutics, Inc. (Amphivena). The milestone represents the development candidate selection against an undisclosed target for the treatment of a certain hematologic malignancy. Affimed, which has a two-fold relationship with Amphivena as both investor and licensor, is due to receive a milestone payment of €7.5 million from Amphivena which will be paid in three installments. In addition, in its role as Amphivena shareholder, Affimed will invest its third and last tranche of €0.32 million ($0.36 million).

TandAbs are tetravalent, bi-functional molecules that selectively bind to a tumor antigen on a cancer cell and, through a second specific binding site, also bind to immune effector cells (NK-cells or T-cells), bringing cancer and immune cells into close proximity. This activates the immune effector cell and enables it to eliminate the cancer cell. In its collaboration with Amphivena/Janssen Biotech, Inc. (Janssen), Affimed has first generated antibodies and subsequently bispecific T-cell TandAbs. Achieving the next milestone, the final development candidate for entering IND-enabling studies was selected.

"Our TandAb platform is the basis for antigen-specific immunotherapies which have the potential to establish new treatment paradigms for various cancers" said Adi Hoess, PhD, CEO of Affimed. "Our achievements in this collaboration underscore the strength of Affimed's TandAb technology to reliably produce development candidates that meet highest selection criteria and may ultimately lead to novel medicines for seriously ill patients."

In July 2013, Amphivena received a commitment of €12.47 million ($14 million) in equity financing from MPM Capital, Aeris Capital and Affimed. Separately, Amphivena entered into an agreement with Janssen that grants Janssen the exclusive right, at Janssen's discretion, to acquire Amphivena following IND approval upon pre-negotiated terms and conditions set forth in the agreement. Janssen has provided Amphivena with an initial upfront payment plus additional contingent payments based on reaching predetermined milestones in return for its rights under the agreement. Amphivena uses the proceeds for the pre-clinical development of a novel therapy for a hematological disorder based on Affimed's proprietary TandAb antibody technology. Affimed has entered into a license and development agreement with Amphivena for the discovery and pre-clinical development of the novel TandAb-based therapy.

About NK-Cell TandAbs, T-Cell TandAbs and Trispecific Abs

Affimed develops TandAbs and Trispecific Abs to substantially increase the efficacy, specificity and/or extend the therapeutic window of current therapeutics. TandAbs and Trispecific Abs are a new generation of proprietary, tumor-cell engaging antibodies with a tetravalent architecture characterized by four binding domains. These tetravalent molecules bind to tumor and immune cells with high affinity. Although generation of such complex antibodies is very challenging, Affimed has succeeded in producing them economically and at high quality.

Leveraging this expertise, Affimed has implemented three platform technologies:

  • Bispecific TandAbs engaging NK-cells (via CD16A)
  • Bispecific TandAbs engaging T-cells (via CD3)
  • Trispecific Abs engaging either NK- or T-cells

Affimed's TandAbs have already demonstrated promising signs of therapeutic activity in patients and robust and efficient production processes for these highly stable molecules have been established in mammalian cell systems. Affimed's Trispecific Abs, which target two distinct tumor epitopes and engage T- or NK-cells to lyse the tumor cells that express both targets, are validated preclinically.

About Affimed N.V.

Affimed (Nasdaq: AFMD ) is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. Affimed's product candidates are being developed in the field of immuno-oncology, which represents an innovative approach to cancer treatment that seeks to harness the body's own immune defenses to fight tumor cells. The most potent cells of the human defense arsenal are types of white blood cells called Natural Killer cells, or NK-cells, and T-cells. Affimed's proprietary, next-generation bispecific antibodies, called TandAbs for their tandem antibody structure, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. Affimed has focused its research and development efforts on three proprietary TandAb programs for which it retains global commercial rights. For more information, please visit www.affimed.com .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements regarding the risk of cessation or delay of any of the ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our clinical development activities, regulatory oversight, product commercialization, intellectual property claims, and the risks, uncertainties and other factors described under the heading "Risk Factors" in Affimed's prospectus dated September 12, 2014 filed with the Securities and Exchange Commission. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

Contact:
Affimed N.V.
Adi Hoess, CEO
Phone: +49 6221 65307-0
E-Mail: IR@affimed.com

Media requests:
Anca Alexandru or Gretchen Schweitzer
MacDougall Biomedical Communications
Phone: +49 89 2424 3494 or
+49 163 613 3359
E-Mail: aalexandru@macbiocom.com

HUG#1905765

Scroll down for more posts ▼

Top 10 Most Recent News Articles

APEC's Shenzhen Signal Is Bigger Than a Two-Day Summit

Updated Category News Views 92

Shenzhen spent two days trying to turn regional anxiety into a workable agenda. The APEC CEO Summit 2026, held November 17 and 18 at the Qianhai International Convention Center, brought together more than 2,000 political and business leaders from all 21 APEC economies and 13 economies outside the group. That is a serious room, not a ceremonial photo line. Still, investors...

Continue Reading
Dallas College Recognition Signals Workforce Value

Updated Category News Views 63

Economic mobility rarely arrives with brass bands, but it can show up in a community-college ranking. Dallas College has landed on TIME and Statista's inaugural America’s Best Community Colleges 2027 list, one of 250 schools selected from roughly 1,100 nationwide. For a region that keeps talking about talent pipelines, this is a useful piece of outside validation—not...

Continue Reading
S&P Global's UBS AI Conference Slot Deserves Attention

Updated Category News Views 109

Thirty Minutes Can Still Matter A half-hour fireside chat is not a quarterly earnings call, and anybody treating it like one is setting themselves up for disappointment. Still, S&P Global CEO Martina Cheung appearing at the UBS Global Technology and AI Conference on December 2 deserves a spot on the calendar for owners of NYSE:SPGI. This is a company sitting in the middle...

Continue Reading
TEN Holdings Raises $1.0 Million as Dilution Looms

Updated Category News Views 66

A Small Raise With a Loud Message Nothing says “we need room to breathe” quite like selling 1,492,500 new shares for $0.67 apiece. TEN Holdings closed a roughly $1.0 million gross equity offering on November 20, 2026, and investors in NASDAQ:XHLD ought to look at this for what it is: a modest cash infusion that comes with immediate dilution. The company gets capital;...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 81

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 73

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 93

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
Delayed Remodels Can Quietly Drain Your Home's Value

Updated Category News Views 91

A pinhole leak has a nasty talent for becoming a demolition budget. That is the plain lesson in Jason Marks' discussion of delayed remodeling for homeowners in Kernersville, North Carolina. People tend to see a worn bathroom, tired kitchen, or drafty window and think, “Not pretty, but it can wait.” Sometimes it can. Sometimes that little delay lets water, rot,...

Continue Reading
Debevoise Builds Its PE M&A Bench With McBain Hire

Updated Category News Views 92

Law-firm hiring rarely makes a market blink, yet this one carries a decent whiff of where the deal work is gathering. Debevoise & Plimpton has brought Jenna McBain into its New York Mergers & Acquisitions Group as a partner, putting another experienced private-equity adviser on a platform the firm plainly intends to keep enlarging. McBain arrives from Weil, Gotshal &...

Continue Reading
Page Library Grant Makes a Practical Case for Access

Updated Category News Views 56

A library card is not much use if a family cannot reach the help behind it. That plain reality sits at the center of AZ Blue Health Choice’s $10,000 contribution to the Page Public Library Family Resource Center, announced November 20, 2026. This is a modest dollar figure in the grand scheme of health care, but it is aimed at the kind of everyday gaps that can become...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Urged to Join Flywire Corporation Securities Class Action

Updated Category News Views 219

Investors Urged to Join Flywire Corporation Securities Class Action The recent developments surrounding Flywire Corporation (NASDAQ: FLYW) have captured the attention of investors, especially those who purchased securities during the specified period. The Rosen Law Firm, known for championing investor rights, is taking the lead in facilitating a securities fraud lawsuit...

Continue Reading
Unicycive Therapeutics Faces Investigation Over Stock Concerns

Updated Category News Views 231

Unicycive Therapeutics Under Investigation for Securities Fraud In recent developments, Pomerantz LLP has initiated an investigation into the possible fraudulent activities involving Unicycive Therapeutics, Inc. (NASDAQ: UNCY). The inquiry focuses on whether the company and its executives may have violated securities laws, an issue that could have implications for many...

Continue Reading
Investors Urged to Act: Join Wolfspeed's Upcoming Class Action

Updated Category News Views 313

Overview of Wolfspeed's Class Action Wolfspeed, Inc. investors are encouraged to take action regarding their stakes in the company as a class action lawsuit surfaces. The Rosen Law Firm, a reputable entity specializing in investor rights, sets a significant deadline for participation in this case. It’s essential for anyone who purchased shares within the specified...

Continue Reading
Pacsun Champions Co-Creation at Music's Grandest Stage

Updated Category News Views 194

Pacsun Champions Co-Creation at Music's Grandest Stage Youth Retailer Debuts Co-Branded Merchandise and Artist Performances As Grammy Weekend celebrates the top talents in music, Pacsun embraces the opportunity to highlight the emerging artists and professionals shaping the future of music. Their approach emphasizes co-creation, access, and cultural participation, crucial...

Continue Reading
Vistra Corp Enhances Financial Stability with Credit Facility Boost

Updated Category News Views 134

Vistra Corp Strengthens Financial Flexibility In a strategic move to enhance its financial flexibility, Vistra Corp. (NYSE:VST), known for delivering electric services, has taken steps to amend its credit agreement. The changes not only extend the maturity date of its credit facility but also expand its borrowing capabilities. This adjustment, effective October 2, 2024,...

Continue Reading